Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis

Maureen J. Aarts, Birgit E. Vriens, Maaike de Boer, Frank P. Peters, Caroline M. Mandigers, M. Wouter Dercksen, Jacqueline M. Stouthard, Jolien Tol, Laurence J. van Warmerdam, Agnes J. van de Wouw, Esther M. Jacobs, Carin C. D. van der Rij, Tineke J. Smilde, Annette W. van der Velden, Nelly Peer, Vivianne C. G. Tjan-Heijnen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objective: The primary outcome of the current study is, whether there is a protective effect of prior chemotherapy or of prior granulocyte colony-stimulating factor (G-CSF) on the next cycle blood cell counts. Methods: Hematologic toxicity was evaluated, based on a randomized phase III study in breast cancer patients (n = 167) with > 20% risk of febrile neutropenia. The primary endpoint was the nadir blood cell counts for patients treated with G-CSF given during all 6 chemotherapy cycles or limited to the first 2 chemotherapy cycles only. Results: For the present analyses, 47 patients were eligible. In the G-CSF 1-6 arm, the median white blood cell count (WBC) and absolute neutrophil count (ANC) nadir slowly decreased from 10.8 x 10(9)/L in cycle 1 to 7.5 x 10(9)/Lin cycle 6 and from 7.1 x 10(9)/L to 5.5 x 10(9) /L, respectively. The median WBC nadir in the G-CSF 1-2 arm decreased from 1.2 x 10(9)/L in cycle 3 to 0.9 x 10(9)/L in cycle 6 and the ANC nadir showed a grade 4 neutropenia of 0.1 x 10(9)/L in cycles 3-6. All patients had ANC recovery to normal levels (>= 1.5 x 10(9)/L) without delay on day 1 of the next cycle. Conclusion: We conclude that there is no protective effect of prior G-CSF or prior chemotherapy use on nadir blood cell counts in subsequent cycles. (C) 2017 S. Karger AG, Basel

Original languageEnglish
Pages (from-to)323-328
Number of pages6
Issue number5
Publication statusPublished - 2017


  • Breast cancer
  • Granulocyte colony-stimulating factor prophylaxis
  • Neutrophil
  • Chemotherapy
  • RISK
  • 1ST

Cite this